# Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

> **NCT03155620** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 1377 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Histiocytic Sarcoma
- Juvenile Xanthogranuloma
- Langerhans Cell Histiocytosis
- Malignant Glioma
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Ependymoma
- Recurrent Ewing Sarcoma
- Recurrent Glioma
- Recurrent Hepatoblastoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Solid Neoplasm
- Recurrent Medulloblastoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Recurrent Primary Central Nervous System Neoplasm
- Recurrent Rhabdoid Tumor
- Recurrent Soft Tissue Sarcoma
- Refractory Ewing Sarcoma
- Refractory Glioma
- Refractory Hepatoblastoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Solid Neoplasm
- Refractory Medulloblastoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Refractory Peripheral Primitive Neuroectodermal Tumor
- Refractory Primary Central Nervous System Neoplasm
- Refractory Rhabdoid Tumor
- Refractory Rhabdomyosarcoma
- Rhabdoid Tumor
- Stage III Osteosarcoma AJCC v7
- Stage III Soft Tissue Sarcoma AJCC v7
- Stage IV Osteosarcoma AJCC v7
- Stage IV Soft Tissue Sarcoma AJCC v7
- Stage IVA Osteosarcoma AJCC v7
- Stage IVB Osteosarcoma AJCC v7
- Wilms Tumor

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **DRUG:** Ensartinib
- **DRUG:** Erdafitinib
- **DRUG:** Ivosidenib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Larotrectinib Sulfate
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Mutation Carrier Screening
- **DRUG:** Olaparib
- **DRUG:** Palbociclib
- **OTHER:** Pharmacological Study
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Radionuclide Imaging
- **DRUG:** Samotolisib
- **DRUG:** Selpercatinib
- **DRUG:** Selumetinib Sulfate
- **DRUG:** Tazemetostat
- **DRUG:** Tipifarnib
- **DRUG:** Ulixertinib
- **DRUG:** Vemurafenib
- **PROCEDURE:** X-Ray Imaging

## Key facts

- **NCT ID:** NCT03155620
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-31
- **Primary completion:** 2025-03-31
- **Final completion:** 2027-01-06
- **Target enrollment:** 1377 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03155620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03155620, "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03155620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*